Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream - 21/08/11
Reprint requests: John L. Aeling, MD, University of Colorado Health Sciences Center, Department of Dermatology, P.O. Box 6510, Mail Stop F703, Aurora, CO 80045-0510.Denver, Colorado
Abstract |
Background |
Systemic interferon is effective in the treatment of mycosis fungoides (MF). Imiquimod is effective in the treatment of some epidermal neoplasms and induces localized interferon production.
Objective |
To evaluate the safety and efficacy of topical imiquimod 5% cream for the treatment of patch and plaque stage MF.
Methods |
Six patients with stage IA to IIB MF were treated with topical imiquimod 5% cream 3 times per week for 12 weeks in this open label pilot study. Index lesions were biopsied pre- and post- treatment, and up to 4 additional treated lesions were monitored for 16 weeks.
Results |
Three of 6 patients had histologic clearance of disease in index lesions, and also demonstrated significant improvement in the clinical scores for all treated lesions. A fourth patient had 2 of 4 lesions respond clinically. Application site reactions were limited to those patients responding to treatment.
Conclusion |
In this preliminary open label study topical imiquimod 5% cream was well tolerated and associated with a histologic and clinical response rate of 50%.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by a grant from 3M Pharmaceuticals, St. Paul, Minnesota. Conflicts of interest: None identified. |
Vol 52 - N° 2
P. 275-280 - février 2005 Retour au numéro
Article précédent
- A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage
- Sewon Kang, Gerald G. Krueger, Emil A. Tanghetti, Deborah Lew-Kaya, John Sefton, Patricia S. Walker, John R. Gibson
- Ultrapotent topical corticosteroid treatment of hemangiomas of infancy
- Maria C. Garzon, Anne W. Lucky, Aimee Hawrot, Ilona J. Frieden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?